MTR 103Alternative Names: MTR-103
Latest Information Update: 13 Jul 2016
At a glance
- Originator Midatech
- Developer Dana-Farber Cancer Institute; Midatech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 18 May 2016 Preclinical trials in Glioblastoma in United Kingdom, USA (unspecified route)